Price$5.73+0.08 (+1.42%)
01:30 PM07:45 PM
News · 26 weeks42+33%
2026-01-182026-07-12
Mix1590d
- SEC Filings8(53%)
- Other6(40%)
- Earnings1(7%)
Latest news
25 items- PREvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during April 2026 to July 2026 of an aggregate of 115,000 restricted stock units (RSUs) of the company’s common stock to 38 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with grant dates and vesting commencement dates ranging from April 7, 2026 through July 8, 2026, as inducements material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).The
- PROne Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical AestheticsIssued on behalf of Conexeu Sciences Inc.Conexeu Sciences Inc. (NASDAQ:CNXU) completed the 12-month P.R.O.O.F phase of its CXU preclinical program, which met its objectives across three pillars, facial, body, and mechanical performance, as it advances a single-formulation regenerative platform toward a predicate-based 510(k).USA News Group News CommentaryRENO, Nev. , July 9, 2026 /CNW/ -- In regenerative medicine, the durable advantage rarely comes from a single product; it comes from a platform that can be pointed at more than one problem. That is the framing behind a milestone from Conexeu Sciences Inc. (NASDAQ:CNXU), a preclinical-stage regenerative tissue company that has completed the P
- SECEvolus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Evolus, Inc. (0001570562) (Filer)
- PREvolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin QualityEvolus, Inc. (NASDAQ:EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an exclusive licensing and distribution agreement with IBSA, a Swiss multinational pharmaceutical company, to develop and commercialize Profhilo® in the United States. Profhilo® is the market-leading injectable in Europe for skin quality, with global brand recognition and availability in more than 70 countries. Profhilo® has a strong track record of clinical performance and commercial success across international markets, with more than 4.8 million treatments administered worldwide since its launch in 2015. The product has
- SECSEC Form EFFECT filed by Evolus Inc.EFFECT - Evolus, Inc. (0001570562) (Filer)
- SECEvolus Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Evolus, Inc. (0001570562) (Filer)
- SECSEC Form S-3 filed by Evolus Inc.S-3 - Evolus, Inc. (0001570562) (Filer)
- PRRegenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItIssued on behalf of Conexeu Sciences Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ:CNXU), Integra LifeSciences Holdings Corporation (NASDAQ:IART), Evolus, Inc. (NASDAQ:EOLS), Bioventus Inc. (NASDAQ:BVS), Mesoblast Limited (NASDAQ:MESO)KEY TAKEAWAYSA fresh Nasdaq debut. Conexeu Sciences Inc. (NASDAQ:CNXU) began trading on May 21, 2026, marking the public-market entry of a Reno-based regenerative tissue platform company targeting wound care, breast reconstruction, and aesthetic medicine — three of the largest unmet-need categories in healthcare today.One platform, multiple markets. Conexeu's proprietary CXU™ extracellular matrix platform is designed to scale across multiple addressabl
- PREvolus to Participate in The Jefferies Global Healthcare ConferenceEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Jefferies Global Healthcare Conference in New York City. The fireside chat will take place on Thursday, June 4th, 2026, at 12:50 PM ET. The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available 90 days after the date of the presentation. About Evolus, Inc. Evolus (NASDAQ:EOLS) is a global performance beauty company redefining the aesthetic injectable market for the
- PREvolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in EuropeEvolus, Inc. (NASDAQ:EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the commercial launch of Estyme® (pronounced "esteem"), its injectable hyaluronic acid (HA) gel collection in Europe, is scheduled for May 16th, marking the company's entry into the international dermal filler market. The Estyme® collection includes four injectable HA gels that will cover a wide range of applications. The collection includes Estyme® Smooth and Estyme® Form, which are currently marketed in the United States under the brand Evolysse®, along with the debut of two products including Estyme® Lips and the flagship product in th
- SECSEC Form 10-Q filed by Evolus Inc.10-Q - Evolus, Inc. (0001570562) (Filer)
- SECEvolus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Evolus, Inc. (0001570562) (Filer)
- PREvolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year OutlookGlobal Net Revenue of $73.1 Million for the First Quarter of 2026, Up 7% Over the Prior Year and Against the Highest Growth Quarter of 2025 GAAP Operating Loss of $6.8 Million and Adjusted EBITDA of $0.6 Million for the First Quarter of 2026, Representing the Second Consecutive Quarter of Positive Adjusted EBITDA and a Significant Improvement from a Loss of $5.5 Million in the Prior Year Period Reaffirms Full-Year 2026 Net Revenue Guidance of $327 Million to $337 Million and Non-GAAP Operating Expenses of $210 Million to $216 Million; Company Continues to Expect to Achieve a Low- to Mid-Single Digit Adjusted EBITDA Margin in 2026 Evolus, Inc. (NASDAQ:EOLS), a global performance be
- SECSEC Form DEF 14A filed by Evolus Inc.DEF 14A - Evolus, Inc. (0001570562) (Filer)
- SECSEC Form DEFA14A filed by Evolus Inc.DEFA14A - Evolus, Inc. (0001570562) (Filer)
- PREvolus to Report First Quarter Financial Results on May 4, 2026Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2026 financial results on Monday, May 4, 2026, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic replay
- PRTelix Appoints David Gill as Non-Executive DirectorMELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 20261. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED. Mr. Gill is a life sciences executive with over 35 years' experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical (including radiopharmaceuticals) and medical device companies. He current
- PREvolus to Participate in the Needham 25th Annual Virtual Healthcare ConferenceEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Virtual Healthcare Conference. The fireside chat will take place on Tuesday, April 14, 2026, at 3:45 PM ET. The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available 90 days after the date of the presentation. About Evolus, Inc. Evolus (NASDAQ:EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of b
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Evolus Inc.SCHEDULE 13G/A - Evolus, Inc. (0001570562) (Subject)
- INSIDERSEC Form 4 filed by Moatazedi David4 - Evolus, Inc. (0001570562) (Issuer)
- INSIDERSEC Form 4 filed by Avelar Rui4 - Evolus, Inc. (0001570562) (Issuer)
- PREvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Evolus, Inc. (NASDAQ:EOLS) a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during March 2026 of an aggregate of 85,516 restricted stock units (RSUs) and 8,635 stock options of the company's common stock to 10 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with grant dates and vesting commencement dates in March 2026 as inducements material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs and options vest
- INSIDERSEC Form 4 filed by Avelar Rui4 - Evolus, Inc. (0001570562) (Issuer)
- INSIDERSEC Form 4 filed by Moatazedi David4 - Evolus, Inc. (0001570562) (Issuer)
- SECEvolus Inc. filed SEC Form 8-K: Leadership Update8-K - Evolus, Inc. (0001570562) (Filer)
EOLS FAQ
7 questionsWhat does Evolus Inc. do?
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.Where does EOLS stock trade?
Evolus Inc. (EOLS) is listed on NASDAQ.What sector and industry is EOLS in?
Evolus Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Evolus Inc. go public?
Evolus Inc. (EOLS) completed its IPO in 2018.What are analysts saying about EOLS?
Evolus Inc. has had 7 recent analyst actions on file. The most recent action was from Needham: Hold on 2025-08-06. Recent price targets range from $1000.00 to $2100.00.What companies are similar to EOLS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare EOLS side-by-side with any of them on Quantisnow.How can I track EOLS on Quantisnow?
Quantisnow aggregates Evolus Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EOLS to receive live email and push alerts on every new disclosure.